Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine as adjunctive treatment in schizophrenia
NCT05654870Phase 3Terminated
- Sponsor
- Neurocrine Biosciences
- Start
- Jan 2023
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valbenazine in schizophrenia, sponsored by Neurocrine Biosciences. Started Jan 2023; status: terminated.
02
Drugs
valbenazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05654870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654870.